Quentin Campbell‐Hewson

429 total citations
13 papers, 101 citations indexed

About

Quentin Campbell‐Hewson is a scholar working on Pulmonary and Respiratory Medicine, Neurology and Molecular Biology. According to data from OpenAlex, Quentin Campbell‐Hewson has authored 13 papers receiving a total of 101 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 4 papers in Neurology and 3 papers in Molecular Biology. Recurrent topics in Quentin Campbell‐Hewson's work include Sarcoma Diagnosis and Treatment (4 papers), Neuroblastoma Research and Treatments (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Quentin Campbell‐Hewson is often cited by papers focused on Sarcoma Diagnosis and Treatment (4 papers), Neuroblastoma Research and Treatments (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Quentin Campbell‐Hewson collaborates with scholars based in United Kingdom, Spain and United States. Quentin Campbell‐Hewson's co-authors include Bruce Morland, Francisco Bautista, Nathalie Gaspar, Franco Locatelli, Isabelle Aerts, Lynley V. Marshall, Soledad Gallego, Adela Cañete, Sandra J. Strauss and Gary D Acton and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Cancer Research.

In The Last Decade

Quentin Campbell‐Hewson

12 papers receiving 100 citations

Peers

Countries citing papers authored by Quentin Campbell‐Hewson

Since Specialization

Citations

This map shows the geographic impact of Quentin Campbell‐Hewson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Quentin Campbell‐Hewson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Quentin Campbell‐Hewson more than expected).

Fields of papers citing papers by Quentin Campbell‐Hewson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Quentin Campbell‐Hewson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Quentin Campbell‐Hewson. The network helps show where Quentin Campbell‐Hewson may publish in the future.

Co-authorship network of co-authors of Quentin Campbell‐Hewson

This figure shows the co-authorship network connecting the top 25 collaborators of Quentin Campbell‐Hewson. A scholar is included among the top collaborators of Quentin Campbell‐Hewson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Quentin Campbell‐Hewson. Quentin Campbell‐Hewson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Title	Journal	Authors	Indexed citations
1	Efficacy and safety of entrectinib in children with extracranial solid or primary central nervous system (CNS) tumors harboring NTRK or ROS1 fusions.	Journal of Clinical Oncology	Ami V. Desai, Giles Robinson et al.	1
2	Perspectives and Expertise in Establishing a Therapeutic Drug Monitoring Programme for Challenging Childhood Cancer Patient Populations	Frontiers in Oncology	S. Barnett, Victoria Holden et al.	4
3	Case Report: Severe Acute Pulmonary COVID-19 in a Teenager Post Autologous Hematopoietic Stem Cell Transplant	Frontiers in Pediatrics	Fabian van der Velden, Stephen Owens et al.	1
4	OLIE, ITCC-082: A Phase II Trial of Lenvatinib Plus Ifosfamide and Etoposide in Relapsed/Refractory Osteosarcoma	Future Oncology	Nathalie Gaspar, Quentin Campbell‐Hewson et al.	5
5	443TiP A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents, and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082)	Annals of Oncology	Nathalie Gaspar, Quentin Campbell‐Hewson et al.	0
6	1668TiP A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082)	Annals of Oncology	Nathalie Gaspar, Quentin Campbell‐Hewson et al.	2
7	Phase I combination dose-finding/phase II expansion cohorts of lenvatinib + etoposide + ifosfamide in patients (pts) aged 2 to ≤ 25 years with relapsed/refractory (r/r) osteosarcoma	Annals of Oncology	Nathalie Gaspar, Francisco Bautista et al.	8
8	Neuroblastoma of the Urinary Bladder in an Infant	SHILAP Revista de lepidopterología	Quentin Campbell‐Hewson et al.	1
9	Single-agent expansion cohort of lenvatinib (LEN) and combination dose-finding cohort of LEN + etoposide (ETP) + ifosfamide (IFM) in patients (pts) aged 2 to ≤25 years with relapsed/refractory osteosarcoma (OS).	Journal of Clinical Oncology	Nathalie Gaspar, Michela Casanova et al.	25
10	Activity of cediranib in alveolar soft part sarcoma (ASPS) confirmed by CASPS (cediranib in ASPS), an international, randomised phase II trial (C2130/A12118).	Journal of Clinical Oncology	Ian Judson, James P. Morden et al.	13
11	A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study	Clinical Cancer Research	Lucas Moreno, Lynley V. Marshall et al.	39
12	Utility of echocardiography in identifying right ventricular extension of Wilm's tumor	Journal of Clinical Ultrasound	Milind Chaudhari, Katrina Wood et al.	1
13	Lateral deviation of toes requires lateral thinking	Archives of Disease in Childhood	Quentin Campbell‐Hewson, Mark Friswell et al.	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact